Ángel Cayo
Publicaciones recientes
- Arévalo B, Bedoya M, Kiper AK, Vergara F, Ramírez D, Mazola Y, Bustos D, Zúñiga R, Cikutovic R, Cayo A, Rinné S, Ramirez-Apan MT, Sepúlveda FV, Cerda O, López-Collazo E, Decher N, Zúñiga L, Gutierrez M, González W. Selective TASK-1 Inhibitor with a Defined Structure-Activity Relationship Reduces Cancer Cell Proliferation and Viability. J Med Chem. 2022;65(22):15014-15027
- Cayo A, Segovia R, Venturini W, Moore-Carrasco R, Valenzuela C, Brown N. Mtor activity and autophagy in senescent cells, a complex partnership. Int J Mol Sci. 2021;22(15)
- Cayo A, Venturini W, Rebolledo-Mira D, Moore-Carrasco R, Herrada AA, Nova-Lamperti E, Valenzuela C, Brown NE. Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy. Int J Mol Sci. 2023;24(11)
- Huilcaman R, Venturini W, Fuenzalida L, Cayo A, Segovia R, Valenzuela C, Brown N, Moore-Carrasco R. Platelets, a Key Cell in Inflammation and Atherosclerosis Progression. Cells. 2022;11(6)
- Valdés F, Arévalo B, Gutiérrez M, García-Castillo V, Salgado-García R, Pérez-Plasencia C, Valenzuela C, Cayo Á, Olate-Briones A, Brown N. Two New Adenosine Derivatives and their Antiproliferative Properties: An In Vitro Evaluation. Anti-Cancer Agents Med Chem. 2022;22(7):1414-1425.
- Valenzuela CA, Quintanilla R, Olate-Briones A, Venturini W, Mancilla D, Cayo A, Moore-Carrasco R, Brown NE. SASP-dependent interactions between senescent cells and platelets modulate migration and invasion of cancer cells. Int J Mol Sci. 2019;20(21)
- Venturini W, Olate-Briones A, Valenzuela C, Méndez D, Fuentes E, Cayo A, Mancilla D, Segovia R, Brown NE, Moore-Carrasco R. Platelet activation is triggered by factors secreted by senescent endothelial HMEC-1 cells in vitro. Int J Mol Sci. 2020;21(9)
- Zúñiga L, Cayo A, González W, Vilos C, Zúñiga R. Potassium Channels as a Target for Cancer Therapy: Current Perspectives. OncoTargets Ther. 2022;15:783-797.
- Zúñiga R, Concha G, Cayo A, Cikutović-Molina R, Arevalo B, González W, Catalán MA, Zúñiga L. Withaferin A suppresses breast cancer cell proliferation by inhibition of the two-pore domain potassium (K2P9) channel TASK-3. Biomed Pharmacother. 2020;129